Oncolytics Biotech Inc. is a biotech company that is focused on developing a new treatment for cancer called pelareorep. The treatment is delivered intravenously and is designed to target cancer through a mechanism of action that involves selective tumor lysis and activation of the innate and adaptive immune systems. This creates an inflamed phenotype, which the company hopes will be effective in treating a range of solid tumors and hematological malignancies. The treatment is described as safe and well-tolerated, and the company is working to bring it to market as soon as possible.